 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
4 July 2000 | Volume 133 Issue 1 | Pages 21-30
Background: Combination antiretroviral therapy with protease inhibitors has transformed HIV infection from a terminal condition into one that is manageable. However, the complexity of regimens makes adherence to therapy difficult.
Objective: To assess the effects of different levels of adherence to therapy on virologic, immunologic, and clinical outcome; to determine modifiable conditions associated with suboptimal adherence; and to determine how well clinicians predict patient adherence.
Design: Prospective, observational study.
Setting: HIV clinics in a Veterans Affairs medical center and a university medical center.
Patients: 99 HIV-infected patients who were prescribed a protease inhibitor and who neither used a medication organizer nor received their medications in an observed setting (such as a jail or nursing home).
Measurements: Adherence was measured by using a microelectronic monitoring system. The adherence rate was calculated as the number of doses taken divided by the number prescribed. Patients were followed for a median of 6 months (range, 3 to 15 months).
Results: During the study period, 45 397 doses of protease inhibitor were monitored in 81 evaluable patients. Adherence was significantly associated with successful virologic outcome (P < 0.001) and increase in CD4 lymphocyte count (P = 0.006). Virologic failure was documented in 22% of patients with adherence of 95% or greater, 61% of those with 80% to 94.9% adherence, and 80% of those with less than 80% adherence. Patients with adherence of 95% or greater had fewer days in the hospital (2.6 days per 1000 days of follow-up) than those with less than 95% adherence (12.9 days per 1000 days of follow-up; P = 0.001). No opportunistic infections or deaths occurred in patients with 95% or greater adherence. Active psychiatric illness was an independent risk factor for adherence less than 95% (P = 0.04). Physicians predicted adherence incorrectly for 41% of patients, and clinic nurses predicted it incorrectly for 30% of patients.
Conclusions: Adherence to protease inhibitor therapy of 95% or greater optimized virologic outcome for patients with HIV infection. Diagnosis and treatment of psychiatric illness should be further investigated as a means to improve adherence to therapy.
Author and Article Information
From Veterans Affairs Medical Center and University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; and University of Nebraska Medical Center, Omaha, Nebraska.
Presented in part at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, 24–27 September 1998, and the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois, 31 January–4 February 1999.
Requests for Single Reprints: Nina Singh, MD, Veterans Affairs Medical Center, Infectious Disease Section, University Drive C, Pittsburgh, PA 15240.
Requests To Purchase Bulk Reprints (minimum, 100 copies): the Reprints Coordinator; phone, 215-351-2657; e-mail, reprints{at}mail.acponline.org.
Current Author Addresses: Dr. Paterson: European Medical Division, University of Pittsburgh Medical Center, 10th Floor, Forbes Tower, 200 Lothrop Street, Pittsburgh, PA 15213.
Dr. Swindells, Mr. Mohr, and Ms. Brester: University of Nebraska Medical Center, 985400 Nebraska Medical Center, Omaha, NE 68198-5400.
Drs. Vergis and Singh, Ms. Squier, and Ms. Wagener: Veterans Affairs Medical Center, University Drive C, Pittsburgh, PA 15240.
Author Contributions: Conception and design: D.L. Paterson, S. Swindells, J. Mohr, M. Brester, E.N. Vergis, C. Squier, N. Singh.
Analysis and interpretation of the data: D.L. Paterson, S. Swindells, M.M. Wagener, N. Singh.
Drafting of the article: D.L. Paterson, N. Singh.
Critical revision of the article for important intellectual content: D.L. Paterson, S. Swindells, C. Squier, M.M. Wagener, N. Singh.
Final approval of the article: D.L. Paterson, S. Swindells, E.N. Vergis, C. Squier, M.M. Wagener, N. Singh.
Provision of study materials or patients: D.L. Paterson, S. Swindells, J. Mohr, M. Brester, E.N. Vergis, C. Squier, N. Singh.
Statistical expertise: M.M. Wagener.
Obtaining of funding: D.L. Paterson, S. Swindells.
Administrative, technical, or logistic support: S. Swindells, J. Mohr, E.N. Vergis, C. Squier, N. Singh.
Collection and assembly of data: D.L. Paterson, S. Swindells, J. Mohr, M. Brester, E.N. Vergis, C. Squier, M.M. Wagener, N. Singh. ARTICLE
Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  L. Dickinson, M. Boffito, S. H. Khoo, M. Schutz, L. J. Aarons, A. L. Pozniak, and D. J. Back Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing J. Antimicrob. Chemother., July 1, 2008; 62(1): 161 - 167. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Simpson, S. Brown, J. Tobias, and For the NGX-4010 C107 Study Group Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy Neurology, June 10, 2008; 70(24): 2305 - 2313. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Whetten, S. Reif, R. Whetten, and L. K. Murphy-McMillan Trauma, Mental Health, Distrust, and Stigma Among HIV-Positive Persons: Implications for Effective Care Psychosom Med, June 1, 2008; 70(5): 531 - 538. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. S. Zaric, A. M. Bayoumi, M. L. Brandeau, and D. K. Owens The Cost-Effectiveness of Counseling Strategies to Improve Adherence to Highly Active Antiretroviral Therapy among Men Who Have Sex with Men Med Decis Making, June 1, 2008; 28(3): 359 - 376. [Abstract] [PDF]
|
|
|
|
 |
|
 K. Torpey, D. Kasonde, and F. Goma The experience of patients taking the lopinavir/ritonavir (LPV/r) tablet compared with the LPV/r soft-gel capsule in Zambia Int J STD AIDS, June 1, 2008; 19(suppl_1): 1 - 4. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Leserman Role of Depression, Stress, and Trauma in HIV Disease Progression Psychosom Med, June 1, 2008; 70(5): 539 - 545. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Hartzell, I. E. Janke, and A. C. Weintrob Impact of depression on HIV outcomes in the HAART era J. Antimicrob. Chemother., May 2, 2008; (2008) dkn193v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. K. T. Wong and J. Ussher How Do Subjectively-Constructed Meanings Ascribed to Anti-HIV Treatments Affect Treatment-Adherent Practice? Qual Health Res, April 1, 2008; 18(4): 458 - 468. [Abstract] [PDF]
|
|
|
|
|
|
J. Shuter Forgiveness of non-adherence to HIV-1 antiretroviral therapy J. Antimicrob. Chemother., April 1, 2008; 61(4): 769 - 773. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Merenstein, M. F. Schneider, C. Cox, R. Schwartz, K. Weber, E. Robison, M. Gandhi, J. Richardson, and M. W. Plankey Association Between Living With Children and Adherence to Highly Active Antiretroviral Therapy in the Women's Interagency HIV Study Pediatrics, April 1, 2008; 121(4): e787 - e793. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Garcia-Gasco, I. Maida, F. Blanco, P. Barreiro, L. Martin-Carbonero, E. Vispo, J. Gonzalez-Lahoz, and V. Soriano Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcome J. Antimicrob. Chemother., March 1, 2008; 61(3): 699 - 704. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hodder Know Your Patient: What Conditions Affect Initial HIV Treatment Success? J Int Assoc Physicians AIDS Care (Chic Ill), March 1, 2008; 7(1_suppl): S5 - S9. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Mok and Q. Minson Drug-related problems in hospitalized patients with HIV infection Am. J. Health Syst. Pharm., January 1, 2008; 65(1): 55 - 59. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Shechter, M. D. Bailey, A. J. Schaefer, and M. S. Roberts The Optimal Time to Initiate HIV Therapy Under Ordered Health States Operations Research, January 1, 2008; 56(1): 20 - 33. [Abstract] [PDF]
|
|
|
|
|
|
B. Clotet Once-daily dosing of nevirapine in HAART J. Antimicrob. Chemother., January 1, 2008; 61(1): 13 - 16. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. March, M. Mak, and S. G. Louie Effects of pharmacists' interventions on patient outcomes in an HIV primary care clinic Am. J. Health Syst. Pharm., December 15, 2007; 64(24): 2574 - 2578. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Balfour, G. A. Tasca, J. Kowal, K. Corace, C. L. Cooper, J. B. Angel, G. Garber, P. A. MacPherson, and D. W. Cameron Development and Validation of the HIV Medication Readiness Scale Assessment, December 1, 2007; 14(4): 408 - 416. [Abstract] [PDF]
|
|
|
|
|
|
M. J. Cuevas Gonzalez, L. O. Valin, M. d. R. Perez-Simon, J. L. Mostaza Fernandez, M. Alcoba Leza, V. M. Sanchez, and the HAART Adherence Working Group of the Province A Prospective Study of Adherence and Virologic Failure in HIV-Infected Patients: Role of a Single Determination of Plasma Levels of Antiretroviral Medications J Int Assoc Physicians AIDS Care (Chic Ill), December 1, 2007; 6(4): 245 - 250. [Abstract] [PDF]
|
|
|
|
 |
|
 J. D. Piette Interactive Behavior Change Technology to Support Diabetes Self-Management: Where do we stand? Diabetes Care, October 1, 2007; 30(10): 2425 - 2432. [Full Text] [PDF]
|
|
|
|
|
|
B. O. Taiwo and R. Murphy Transmitted Resistance: An Overview and Its Potential Relevance to the Management of HIV-Infected Persons in Resource-Limited Settings J Int Assoc Physicians AIDS Care (Chic Ill), September 1, 2007; 6(3): 188 - 197. [Abstract] [PDF]
|
|
|
|
|
|
L. Campero, C. Herrera, T. Kendall, and M. Caballero Bridging the Gap Between Antiretroviral Access and Adherence in Mexico Qual Health Res, May 1, 2007; 17(5): 599 - 611. [Abstract] [PDF]
|
|
|
|
 |
|
 J. B. Nachega, M. Hislop, D. W. Dowdy, R. E. Chaisson, L. Regensberg, and G. Maartens Adherence to Nonnucleoside Reverse Transcriptase Inhibitor Based HIV Therapy and Virologic Outcomes Ann Intern Med, April 17, 2007; 146(8): 564 - 573. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Parsons, E. Rosof, and B. Mustanski Patient-related Factors Predicting HIV Medication Adherence among Men and Women with Alcohol Problems J Health Psychol, March 1, 2007; 12(2): 357 - 370. [Abstract] [PDF]
|
|
|
|
 |
|
 R C. Rathbun, K. C Farmer, S. M Lockhart, and J. R Stephens Validity of a Stage of Change Instrument in Assessing Medication Adherence in Indigent Patients with HIV Infection Ann. Pharmacother., February 1, 2007; 41(2): 208 - 214. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Braithwaite, M. S. Roberts, and A. C. Justice Incorporating Quality of Evidence into Decision Analytic Modeling Ann Intern Med, January 16, 2007; 146(2): 133 - 141. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Javanbakht, P. Prosser, T. Grimes, M. Weinstein, and C. Farthing Efficacy of an Individualized Adherence Support Program with Contingent Reinforcement Among Nonadherent HIV-Positive Patients: Results From a Randomized Trial. J Int Assoc Physicians AIDS Care (Chic Ill), December 1, 2006; 5(4): 143 - 150. [Abstract] [PDF]
|
|
|
|
|
|
P. L. Williams, D. Storm, G. Montepiedra, S. Nichols, B. Kammerer, P. A. Sirois, J. Farley, K. Malee, and for the PACTG 219C Team Predictors of Adherence to Antiretroviral Medications in Children and Adolescents With HIV Infection Pediatrics, December 1, 2006; 118(6): e1745 - e1757. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Braithwaite, S. Shechter, M. S. Roberts, A. Schaefer, D. R. Bangsberg, P. R. Harrigan, and A. C. Justice Explaining variability in the relationship between antiretroviral adherence and HIV mutation accumulation J. Antimicrob. Chemother., November 1, 2006; 58(5): 1036 - 1043. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Ramer, D. Johnson, L. Chan, and M. T. Barrett The Effect of HIV/AIDS Disease Progression on Spirituality and Self-Transcendence in a Multicultural Population. J Transcult Nurs, July 1, 2006; 17(3): 280 - 289. [Abstract] [PDF]
|
|
|
|
|
|
M. Oette, A. Kroidl, K. Gobels, A. Stabbert, M. Menge, A. Sagir, D. Kuschak, T. O'Hanley, J. G. Bode, and D. Haussinger Predictors of short-term success of antiretroviral therapy in HIV infection J. Antimicrob. Chemother., July 1, 2006; 58(1): 147 - 153. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E K. Hester, H. V Chandler, and K. M Sims Fosamprenavir: Drug Development for Adherence Ann. Pharmacother., July 1, 2006; 40(7): 1301 - 1310. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. C. Rudorf and S. A. Krikorian Adverse Effects Associated With Antiretroviral Therapy and Potential Management Strategies Journal of Pharmacy Practice, August 1, 2005; 18(4): 258 - 277. [Abstract] [PDF]
|
|
|
|
|
|
M. F. Parry, P. Wright, J. Stewart, G. X. McLeod, J. Tucker, and A. R. Weinberg Impact of an Adherence Program on the Health and Outlook of HIV-Infected Patients Failing Antiretroviral Therapy. J Int Assoc Physicians AIDS Care (Chic Ill), July 1, 2005; 4(3): 59 - 65. [Abstract] [PDF]
|
|
|
|
|
|
K. Shannon, T. Kerr, C. Lai, T. Ishida, E. Wood, J. S. G. Montaner, R. S. Hogg, and M. W. Tyndall Nonadherence to antiretroviral therapy among a community with endemic rates of injection drug use. J Int Assoc Physicians AIDS Care (Chic Ill), July 1, 2005; 4(3): 66 - 72. [Abstract] [PDF]
|
|
|
|
|
|
J. D. Scott Simplifying the treatment of HIV infection with ritonavir-boosted protease inhibitors in antiretroviral-experienced patients Am. J. Health Syst. Pharm., April 15, 2005; 62(8): 809 - 815. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. L Anderson Pharmacologic Perspectives for Once-Daily Antiretroviral Therapy Ann. Pharmacother., November 1, 2004; 38(11): 1924 - 1934. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ammassari, A. Antinori, M. S. Aloisi, M. P. Trotta, R. Murri, L. Bartoli, A. d. Monforte, A. W. Wu, and F. Starace Depressive Symptoms, Neurocognitive Impairment, and Adherence to Highly Active Antiretroviral Therapy Among HIV-Infected Persons Psychosomatics, October 1, 2004; 45(5): 394 - 402. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Arribas The rise and fall of triple nucleoside reverse transcriptase inhibitor (NRTI) regimens J. Antimicrob. Chemother., September 1, 2004; 54(3): 587 - 592. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Cook, D. Grey, J. Burke, M. H. Cohen, A. C. Gurtman, J. L. Richardson, T. E. Wilson, M. A. Young, and N. A. Hessol Depressive Symptoms and AIDS-Related Mortality Among a Multisite Cohort of HIV-Positive Women Am J Public Health, July 1, 2004; 94(7): 1133 - 1140. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Bangsberg, A. R. Moss, and S. G. Deeks Paradoxes of adherence and drug resistance to HIV antiretroviral therapy J. Antimicrob. Chemother., May 1, 2004; 53(5): 696 - 699. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Gulick, H. J. Ribaudo, C. M. Shikuma, S. Lustgarten, K. E. Squires, W. A. Meyer III, E. P. Acosta, B. R. Schackman, C. D. Pilcher, R. L. Murphy, et al. Triple-Nucleoside Regimens versus Efavirenz-Containing Regimens for the Initial Treatment of HIV-1 Infection N. Engl. J. Med., April 29, 2004; 350(18): 1850 - 1861. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. S. Furfine, C. T. Baker, M. R. Hale, D. J. Reynolds, J. A. Salisbury, A. D. Searle, S. D. Studenberg, D. Todd, R. D. Tung, and A. Spaltenstein Preclinical Pharmacology and Pharmacokinetics of GW433908, a Water-Soluble Prodrug of the Human Immunodeficiency Virus Protease Inhibitor Amprenavir Antimicrob. Agents Chemother., March 1, 2004; 48(3): 791 - 798. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Singla, G. E. MacKinnon III, K. J. MacKinnon, W. Younis, and B. Field Interdisciplinary Approach to Teaching Medication Adherence to Pharmacy and Osteopathic Medical Students J Am Osteopath Assoc, March 1, 2004; 104(3): 127 - 132. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Bulgheroni, P. Citterio, F. Croce, M. Lo Cicero, O. Vigano, F. Soster, T.-C. Chou, M. Galli, and S. Rusconi Analysis of protease inhibitor combinations in vitro: activity of lopinavir, amprenavir and tipranavir against HIV type 1 wild-type and drug-resistant isolates J. Antimicrob. Chemother., March 1, 2004; 53(3): 464 - 468. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Wood, K. Arasteh, H.-J. Stellbrink, E. Teofilo, F. Raffi, R. B. Pollard, J. Eron, J. Yeo, J. Millard, M. B. Wire, et al. Six-Week Randomized Controlled Trial To Compare the Tolerabilities, Pharmacokinetics, and Antiviral Activities of GW433908 and Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients Antimicrob. Agents Chemother., January 1, 2004; 48(1): 116 - 123. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Preston, P. J. Piliero, J. A. Bilello, D. S. Stein, W. T. Symonds, and G. L. Drusano In Vitro-In Vivo Model for Evaluating the Antiviral Activity of Amprenavir in Combination with Ritonavir Administered at 600 and 100 Milligrams, Respectively, Every 12 Hours Antimicrob. Agents Chemother., November 1, 2003; 47(11): 3393 - 3399. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. V. Havlir, M. C. Strain, M. Clerici, C. Ignacio, D. Trabattoni, P. Ferrante, and J. K. Wong Productive Infection Maintains a Dynamic Steady State of Residual Viremia in Human Immunodeficiency Virus Type 1-Infected Persons Treated with Suppressive Antiretroviral Therapy for Five Years J. Virol., October 15, 2003; 77(20): 11212 - 11219. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. T. Moskowitz Positive Affect Predicts Lower Risk of AIDS Mortality Psychosom Med, July 1, 2003; 65(4): 620 - 626. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Escobar, M. Campo, J. Martin, C. Fernandez-Shaw, F. Pulido, and R. Rubio Factors Affecting Patient Adherence to Highly Active Antiretroviral Therapy Ann. Pharmacother., June 1, 2003; 37(6): 775 - 781. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Frenkel, Y. Wang, G. H. Learn, J. L. McKernan, G. M. Ellis, K. M. Mohan, S. E. Holte, S. M. De Vange, D. M. Pawluk, A. J. Melvin, et al. Multiple Viral Genetic Analyses Detect Low-Level Human Immunodeficiency Virus Type 1 Replication during Effective Highly Active Antiretroviral Therapy J. Virol., May 15, 2003; 77(10): 5721 - 5730. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Inouye, S. T. Bogardus Jr, C. S. Williams, L. Leo-Summers, and J. V. Agostini The Role of Adherence on the Effectiveness of Nonpharmacologic Interventions: Evidence From the Delirium Prevention Trial Arch Intern Med, April 28, 2003; 163(8): 958 - 964. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Volberding, K. R. Baker, and A. M. Levine Human Immunodeficiency Virus Hematology Hematology, January 1, 2003; 2003(1): 294 - 313. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H K Thaker and M H Snow HIV viral suppression in the era of antiretroviral therapy Postgrad. Med. J., January 1, 2003; 79(927): 36 - 42. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.H. Hinkin, S.A. Castellon, R.S. Durvasula, D.J. Hardy, M.N. Lam, K.I. Mason, D. Thrasher, M.B. Goetz, and M. Stefaniak Medication adherence among HIV+ adults: Effects of cognitive dysfunction and regimen complexity Neurology, December 24, 2002; 59(12): 1944 - 1950. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Safren, A. S. Radomsky, M. W. Otto, and E. Salomon Predictors of Psychological Well-Being in a Diverse Sample of HIV-Positive Patients Receiving Highly Active Antiretroviral Therapy Psychosomatics, December 1, 2002; 43(6): 478 - 485. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
Article
